MedTrace Logo

Cannabidiol - an in Vivo Innovative Drug Delivery Study

NCT03471559 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2020-07-01

No results posted yet for this study

Summary

Basic characterization of the drug delivery system for cannabidiol. A comparative bioavailability study.

Conditions

  • Pharmacokinetics, Bioavailability

Interventions

DRUG

Cannabidiol

single or multiple dosing

Sponsors & Collaborators

  • Central Institute of Mental Health, Mannheim

    lead OTHER

Principal Investigators

  • Uwe Fuhr, MD · Department I of Pharmacology, University of Cologne

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-12-10
Primary Completion
2019-06-30
Completion
2019-08-29

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03471559 on ClinicalTrials.gov